Namwiwat Medical PCLBKK:NAM -1.73%40 ROA % is 1.64% as of Mar. 2026, which is 83% below its 10-year median of 9.92. GuruFocus rates BKK:NAM with a GF Score™ of 40/100 and a GF Value™ of ฿6.04 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 856 Medical Devices & Instruments companies, Namwiwat Medical PCL ranks better than 59.81% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Namwiwat Medical PCL's annualizedNet Income for the quarter that ended in Mar. 2026 was ฿49 Mil.
Namwiwat Medical PCL's average Total Assets over the quarter that ended in Mar. 2026 was ฿2,969 Mil. Therefore, Namwiwat Medical PCL's annualized ROA % for the quarter that ended in Mar. 2026 was 1.64%.
The historical rank and industry rank for Namwiwat Medical PCL's ROA % or its related term are showing as below:
BKK:NAM'
s ROA % Range Over the Past 10 Years
Min: 2.56 Med: 9.92 Max: 18.59
Current: 2.56
During the past 6 years, Namwiwat Medical PCL's highest ROA % was 18.59%. The lowest was 2.56%. And the median was 9.92%.
BKK:NAM's ROA % is ranked better than 59.81% of 856
companies
in the Medical Devices & Instruments industry
Industry Median: 0.545
vs BKK:NAM: 2.56
Namwiwat Medical PCL (BKK:NAM) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Namwiwat Medical PCL's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Namwiwat Medical PCL ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Namwiwat Medical PCL's ROA % distribution charts can be found below:
* The bar in red indicates where Namwiwat Medical PCL's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Namwiwat Medical PCL (BKK:NAM) has a ROA % of 1.64% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Namwiwat Medical PCL and its competitors. This is 83% below median its historical median of 9.92. Over the past decade, Namwiwat Medical PCL's ROA % has ranged from 2.56 to 18.59. According to the industry distribution chart, Namwiwat Medical PCL ranks #344 out of 856 companies in the Medical Devices & Instruments industry, placing it in the top 40.2%.
Is Namwiwat Medical PCL's ROA % too high?
Namwiwat Medical PCL's current ROA % of 1.64% is 83% below median its 10-year median of 9.92. Over the past 10 years, this metric has ranged from a low of 2.56 to a high of 18.59. The Medical Devices & Instruments industry median ROA % is 0.55. Namwiwat Medical PCL's value of 1.64% is 200.9% above this industry median. Based on the distribution chart, Namwiwat Medical PCL ranks #344 out of 856 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Namwiwat Medical PCL has a GF Score™ of 40/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Namwiwat Medical PCL's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Namwiwat Medical PCL ranks #344 out of 856 companies for ROA %. This puts Namwiwat Medical PCL in the upper half of its industry. The industry median ROA % is 0.55. Namwiwat Medical PCL's value of 1.64% is 200.9% above this benchmark. Historically, Namwiwat Medical PCL's own ROA % has ranged from 2.56 to 18.59 over the past decade. While the company's 10-year median is 9.92 vs. the industry median of 0.55, Namwiwat Medical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.55, based on 856 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Namwiwat Medical PCL's current ROA % of 1.64% is 200.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Namwiwat Medical PCL and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Namwiwat Medical PCL's current ROA % is 1.64%, which is 83% below median its own 10-year median of 9.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Namwiwat Medical PCL stock overvalued right now?
Based on GuruFocus' analysis, Namwiwat Medical PCL (BKK:NAM) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿6.04, compared to a current price of ฿3.40 — trading 43.7% below its estimated fair value. The current ROA % is 1.64%, which is 83% below median its 10-year median of 9.92 and 200.9% above the Medical Devices & Instruments industry median of 0.55. Namwiwat Medical PCL's overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Namwiwat Medical PCL (BKK:NAM), the current ROA % is 1.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Namwiwat Medical PCL (BKK:NAM) Overvalued in 2026?
Based on GuruFocus' analysis, Namwiwat Medical PCL stock appears to be undervalued.
The current stock price of ฿3.40 is trading 43.7% below its estimated GF Value™ of ฿6.04.
GuruFocus considers Namwiwat Medical PCL to be Significantly Undervalued.
Key valuation signals for BKK:NAM:
ROA %: 1.64% (83% below median its 10-year median of 9.92)
GF Value™: ฿6.04 vs. price of ฿3.40 (43.7% below fair value)
Industry Position: 200.9% above the Medical Devices & Instruments median (#344 of 856)
No single metric tells the full story. See the BKK:NAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Namwiwat Medical Corp PCL operates a manufacturing business, importing and distributing Medical tools and equipment for cleaning and disinfecting medical equipment in hospitals and nursing homes in accordance with public health standards. The Group has a total of three reporting segments as follows: Medical equipment manufacturing and distribution segment; Medical supplies manufacturing and distribution segment; CSSD disinfection Medical equipment maintenance services segment, and waste services segment. The Group operates its business in one geography, only in Thailand.
40GF Score
Get the complete analysis for BKK:NAM
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NAM has been successfully added to your 
